Some call it the most important promo in professional wrestling history — and honestly they might be right. Either way, one thing we can say with certainty is that it's exactly 30 years today since ...

Casey Gallagher, MD, is a board-certified dermatologist and clinical professor based in Colorado. Valacyclovir may be easier to take than acyclovir because of its simpler dosing schedule. Both ...

To begin their journeys in this year's World Cup, Iraq and Norway will share the pitch at 6 p.m. ET from Gillette Stadium. For the first time since 1986, Iraq will be present at the FIFA World Cup.

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Incyte INCY6.87%increase; up pointing triangle has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company’s hematology portfolio into bleeding ...

While computer monitors seem to be more or less the same once you get past the size and the ports, that’s not really true. Even the most common type, the humble LCD, has a lot of sub-types. And while ...

June 8 (Reuters) - Incyte (INCY.O), opens new tab said on Monday it will buy Vega Therapeutics, a wholly owned subsidiary of privately held Star Therapeutics, in a deal ‌worth up to $2 billion, ...

Bill Meury, Incyte's chief executive. Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug candidate for bleeding disorders.

Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential. Incyte is adding a star to its ...

Incyte, a drugmaker with a heavy focus on blood diseases and cancers, plans to take control of an experimental medicine that could help control bleeding in a variety of disorders. Vega Therapeutics, a ...